A 50-year old patient with recurrent cancer involving tumours in both the brain and spinal cord has been treated with a chimeric antigen receptor (CAR) T cell therapy targeting an antigen that is overexpressed in a majority of glioblastomas.
The cell-therapy company TiGenix NV has raised gross proceeds of $35.65 million in an initial public offering of its shares on the Nasdaq exchange in the US in order to support the clinical development of its allogeneic product portfolio.
A patient with KRAS mutant metastatic colorectal cancer has been successfully treated with an autologous T cell receptor therapy, suggesting there may be a path forward for tackling difficult solid tumours, according to Kite Pharma Inc.
The Food and Drug Administration (FDA) has approved Maci, an autologous tissue-engineered product for the repair of cartilage defects in the knee, the first product of its kind to be authorised for the US. Maci is manufactured by Vericel Corp, formerly Aastrom Biosciences Inc.
ReNeuron Plc has reported positive data from a Phase 2 trial of its allogeneic cell therapy for patients disabled by a stroke and plans to apply to regulatory authorities in the US and Europe to begin a pivotal study that could lead to possible registration.
The cell-therapy company TiGenix NV has announced plans to make an initial public offering of its shares on the Nasdaq exchange in the US in order to raise money for the clinical development of its portfolio. The company is already listed on Euronext Brussels.
Spark Therapeutics Inc has agreed to make a $10 million cash payment plus an equity investment in Selecta Biosciences Inc for access to a nanoparticle technology that could be used to modulate the immune system and allow repeat dosing of a gene therapy.
Regulators in both the US and Europe are preparing for the first submissions of a new class of cancer drugs that have been shown to vanquish cancer in some patients b
Cell Medica Ltd has expanded an existing partnership with the Baylor College of Medicine in Texas, US to develop allogeneic cell therapies based on engineered immune cells generated from healthy donors. The cells are invariant natural killer T (NKT) cells.
If the cell therapy industry were a housing project, then arguably it would be at the construction stage – deciding what materials are needed to make a safe and durable product. Manufacture is a key issue for the industry, but one that is just now being confronted, according to participants at a meeting of the Alliance for Regenerative Medicine that took place in London on 3 November.